Do analysts recommend ALVR or CUE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, ALVR or CUE?

Cue Biopharma has higher revenue and earnings than AlloVir. Cue Biopharma is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Cue Biopharma $27.47M 3.75 -$26.60M -$5.58 N/A

Is ALVR or CUE more profitable?

AlloVir has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. AlloVir's return on equity of -71.03% beat Cue Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Cue Biopharma -59.65% -98.30% -53.69%

Do analysts recommend IBIO or ALVR?

iBio currently has a consensus target price of $5.00, suggesting a potential upside of 195.86%. Given iBio's stronger consensus rating and higher possible upside, research analysts clearly believe iBio is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iBio 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.13 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, IBIO or ALVR?

iBio has higher revenue and earnings than AlloVir. iBio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iBio $400K 209.90 -$18.38M -$0.58 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is IBIO or ALVR more profitable?

iBio's return on equity of -53.86% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% AlloVir N/A -71.03% -61.27%

Do analysts rate ALVR or PMN?

Promis Neurosciences has a consensus price target of $26.50, indicating a potential upside of 156.04%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts plainly believe Promis Neurosciences is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Promis Neurosciences 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has stronger valuation & earnings, ALVR or PMN?

Promis Neurosciences is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Promis Neurosciences N/A N/A -$39.72M -$14.51 N/A

Is ALVR or PMN more profitable?

AlloVir's return on equity of -71.03% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Promis Neurosciences N/A -237.99% -151.04%

Do analysts rate ALVR or FTLF?

FitLife Brands has a consensus target price of $21.50, indicating a potential upside of 95.28%. Given FitLife Brands' stronger consensus rating and higher possible upside, analysts clearly believe FitLife Brands is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 FitLife Brands 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has better earnings and valuation, ALVR or FTLF?

FitLife Brands has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A FitLife Brands $81.46M 1.27 $6.33M $0.60 18.35

Is ALVR or FTLF more profitable?

FitLife Brands has a net margin of 6.64% compared to AlloVir's net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% FitLife Brands 6.64% 18.31% 8.21%

Do analysts recommend ALVR or ATRA?

Atara Biotherapeutics has a consensus price target of $9.50, indicating a potential downside of 8.74%. Given Atara Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Atara Biotherapeutics is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Atara Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

AlloVir (ALVR) Competitors

$4.33 -0.03 (-0.69%)

As of 06/12/2026

Compare

ALVR vs. CUE, IBIO, PMN, FTLF, and ATRA

Should you buy AlloVir stock or one of its competitors? MarketBeat compares AlloVir with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AlloVir include Cue Biopharma (CUE), iBio (IBIO), Promis Neurosciences (PMN), FitLife Brands (FTLF), and Atara Biotherapeutics (ATRA). These companies are all part of the "pharmaceutical products" industry.

How does AlloVir compare to Cue Biopharma?

AlloVir (NASDAQ:ALVR) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

Cue Biopharma has higher revenue and earnings than AlloVir. Cue Biopharma is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Cue Biopharma	$27.47M	3.75	-$26.60M	-$5.58	N/A

AlloVir has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. AlloVir's return on equity of -71.03% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Cue Biopharma	-59.65%	-98.30%	-53.69%

66.1% of AlloVir shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 32.1% of AlloVir shares are held by company insiders. Comparatively, 14.6% of Cue Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.51, meaning that its share price is 151% more volatile than the broader market.

In the previous week, Cue Biopharma had 1 more articles in the media than AlloVir. MarketBeat recorded 1 mentions for Cue Biopharma and 0 mentions for AlloVir. Cue Biopharma's average media sentiment score of 1.87 beat AlloVir's score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Cue Biopharma	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cue Biopharma beats AlloVir on 8 of the 13 factors compared between the two stocks.

How does AlloVir compare to iBio?

iBio (NASDAQ:IBIO) and AlloVir (NASDAQ:ALVR) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

iBio has higher revenue and earnings than AlloVir. iBio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	209.90	-$18.38M	-$0.58	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

iBio's return on equity of -53.86% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
AlloVir	N/A	-71.03%	-61.27%

iBio currently has a consensus target price of $5.00, suggesting a potential upside of 195.86%. Given iBio's stronger consensus rating and higher possible upside, research analysts clearly believe iBio is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

iBio has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

In the previous week, iBio had 4 more articles in the media than AlloVir. MarketBeat recorded 4 mentions for iBio and 0 mentions for AlloVir. iBio's average media sentiment score of 0.60 beat AlloVir's score of 0.00 indicating that iBio is being referred to more favorably in the media.

Company	Overall Sentiment
iBio	Positive
AlloVir	Neutral

7.9% of iBio shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 2.8% of iBio shares are held by company insiders. Comparatively, 32.1% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

iBio beats AlloVir on 12 of the 15 factors compared between the two stocks.

How does AlloVir compare to Promis Neurosciences?

AlloVir (NASDAQ:ALVR) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

AlloVir's return on equity of -71.03% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Promis Neurosciences	N/A	-237.99%	-151.04%

66.1% of AlloVir shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 32.1% of AlloVir shares are held by insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Promis Neurosciences is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

In the previous week, Promis Neurosciences had 12 more articles in the media than AlloVir. MarketBeat recorded 12 mentions for Promis Neurosciences and 0 mentions for AlloVir. Promis Neurosciences' average media sentiment score of 0.75 beat AlloVir's score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Promis Neurosciences	Positive

Promis Neurosciences has a consensus price target of $26.50, indicating a potential upside of 156.04%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts plainly believe Promis Neurosciences is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.19, indicating that its share price is 119% less volatile than the broader market.

Summary

Promis Neurosciences beats AlloVir on 8 of the 14 factors compared between the two stocks.

How does AlloVir compare to FitLife Brands?

AlloVir (NASDAQ:ALVR) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

66.1% of AlloVir shares are owned by institutional investors. Comparatively, 2.3% of FitLife Brands shares are owned by institutional investors. 32.1% of AlloVir shares are owned by insiders. Comparatively, 61.4% of FitLife Brands shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

FitLife Brands has a net margin of 6.64% compared to AlloVir's net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
FitLife Brands	6.64%	18.31%	8.21%

FitLife Brands has a consensus target price of $21.50, indicating a potential upside of 95.28%. Given FitLife Brands' stronger consensus rating and higher possible upside, analysts clearly believe FitLife Brands is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

FitLife Brands has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
FitLife Brands	$81.46M	1.27	$6.33M	$0.60	18.35

In the previous week, FitLife Brands had 2 more articles in the media than AlloVir. MarketBeat recorded 2 mentions for FitLife Brands and 0 mentions for AlloVir. FitLife Brands' average media sentiment score of 0.93 beat AlloVir's score of 0.00 indicating that FitLife Brands is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
FitLife Brands	Positive

AlloVir has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, FitLife Brands has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market.

Summary

FitLife Brands beats AlloVir on 13 of the 15 factors compared between the two stocks.

How does AlloVir compare to Atara Biotherapeutics?

AlloVir (NASDAQ:ALVR) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Atara Biotherapeutics has a consensus price target of $9.50, indicating a potential downside of 8.74%. Given Atara Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Atara Biotherapeutics is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

AlloVir has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. AlloVir's return on equity of -71.03% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

Atara Biotherapeutics has higher revenue and earnings than AlloVir. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Atara Biotherapeutics	$120.77M	0.78	$32.69M	-$0.67	N/A

66.1% of AlloVir shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Atara Biotherapeutics had 3 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Atara Biotherapeutics and 0 mentions for AlloVir. Atara Biotherapeutics' average media sentiment score of 0.51 beat AlloVir's score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Atara Biotherapeutics	Positive

AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market.

Summary

Atara Biotherapeutics beats AlloVir on 11 of the 15 factors compared between the two stocks.

Get AlloVir News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALVR vs. The Competition

Export

Metric	AlloVir	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$21.84M	$349.04M	$6.53B	$12.05B
Dividend Yield	N/A	N/A	2.67%	5.67%
P/E Ratio	-0.21	N/A	24.22	24.42
Price / Sales	N/A	170.73	511.60	109.90
Price / Cash	N/A	22.44	27.48	37.92
Price / Book	0.15	4.76	10.65	6.82
Net Income	-$190.42M	-$141.03M	$3.57B	$337.56M
7 Day Performance	-2.48%	0.72%	0.58%	1.17%
1 Month Performance	-17.05%	-4.63%	1.54%	3.16%
1 Year Performance	64.02%	56.79%	25.40%	30.58%

AlloVir Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALVR AlloVir	N/A	$4.33 -0.7%	N/A	+64.0%	$21.84M	N/A	N/A	110	High Trading Volume
CUE Cue Biopharma	0.3514 of 5 stars	$28.62 +18.9%	N/A	-95.5%	$97.36M	$27.47M	N/A	60	Positive News Gap Up
IBIO iBio	3.8526 of 5 stars	$1.76 -6.9%	$4.75 +169.9%	N/A	$93.89M	$400K	N/A	100
PMN Promis Neurosciences	4.0198 of 5 stars	$10.15 -2.5%	$26.50 +161.1%	-20.3%	$93.35M	N/A	N/A	5	Gap Up
FTLF FitLife Brands	4.5182 of 5 stars	$9.72 -1.9%	$21.50 +121.2%	-21.4%	$93.07M	$81.46M	16.09	20	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALVR) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AlloVir (ALVR) Competitors

ALVR vs. CUE, IBIO, PMN, FTLF, and ATRA

How does AlloVir compare to Cue Biopharma?

Summary

How does AlloVir compare to iBio?

Summary

How does AlloVir compare to Promis Neurosciences?

Summary

How does AlloVir compare to FitLife Brands?

Summary

How does AlloVir compare to Atara Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVR vs. The Competition

AlloVir Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AlloVir (ALVR) Competitors

ALVR vs. CUE, IBIO, PMN, FTLF, and ATRA

How does AlloVir compare to Cue Biopharma?

Which has preferable valuation and earnings, ALVR or CUE?

Is ALVR or CUE more profitable?

Do institutionals and insiders hold more shares of ALVR or CUE?

Which has more risk & volatility, ALVR or CUE?

Does the media favor ALVR or CUE?

Do analysts recommend ALVR or CUE?

Summary

How does AlloVir compare to iBio?

Which has higher valuation & earnings, IBIO or ALVR?

Is IBIO or ALVR more profitable?

Do analysts recommend IBIO or ALVR?

Which has more volatility & risk, IBIO or ALVR?

Does the media prefer IBIO or ALVR?

Do insiders and institutionals hold more shares of IBIO or ALVR?

Summary

How does AlloVir compare to Promis Neurosciences?

Is ALVR or PMN more profitable?

Do insiders & institutionals believe in ALVR or PMN?

Which has stronger valuation & earnings, ALVR or PMN?

Does the media favor ALVR or PMN?

Do analysts rate ALVR or PMN?

Which has more risk & volatility, ALVR or PMN?

Summary

How does AlloVir compare to FitLife Brands?

Do institutionals and insiders believe in ALVR or FTLF?

Is ALVR or FTLF more profitable?

Do analysts rate ALVR or FTLF?

Which has better earnings and valuation, ALVR or FTLF?

Does the media favor ALVR or FTLF?

Which has more volatility & risk, ALVR or FTLF?

Summary

How does AlloVir compare to Atara Biotherapeutics?

Do analysts recommend ALVR or ATRA?

Is ALVR or ATRA more profitable?

Which has preferable valuation & earnings, ALVR or ATRA?

Do institutionals & insiders believe in ALVR or ATRA?

Does the media refer more to ALVR or ATRA?

Which has more volatility & risk, ALVR or ATRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVR vs. The Competition

AlloVir Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools